Multifunctional actions of approved and candidate stroke drugs
Ischemic stroke causes brain damage by multiple pathways. Previous stroke trials have demonstrated that drugs targeting one or only a few of these pathways fail to improve clinical outcome after stroke. Drugs with multimodal actions have been suggested to overcome this challenge. In this review, we...
Na minha lista:
| Publicado no: | Neurotherapeutics |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer-Verlag
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084255/ https://ncbi.nlm.nih.gov/pubmed/19110198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nurt.2008.10.032 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| id |
pubmed-5084255 |
|---|---|
| record_format |
dspace |
| spelling |
pubmed-50842552016-10-31 Multifunctional actions of approved and candidate stroke drugs Minnerup, Jens Schäbitz, Wolf-Rüdiger Neurotherapeutics Review Article Ischemic stroke causes brain damage by multiple pathways. Previous stroke trials have demonstrated that drugs targeting one or only a few of these pathways fail to improve clinical outcome after stroke. Drugs with multimodal actions have been suggested to overcome this challenge. In this review, we describe the mechanisms of action of agents approved for secondary prevention of ischemic stroke, such as antiplatelet, antihypertensive, and lipid-lowering drugs. These drugs exhibit considerable properties beyond their classical mechanisms, including neuroprotective and neuroregenerative properties. In addition, candidate stroke drugs currently studied in clinical phase III trials are described. Among these, albumin, hematopoietic growth factors, and citicoline have been identified as promising agents with multiple mechanisms. These drugs offer hope that additional treatment options for the acute phase after a stroke will become available in the near future. Springer-Verlag 2009-01 /pmc/articles/PMC5084255/ /pubmed/19110198 http://dx.doi.org/10.1016/j.nurt.2008.10.032 Text en © The American Society for Experimental NeuroTherapeutics, Inc. 2009 |
| institution |
US NLM |
| collection |
PubMed Central |
| language |
Inglês |
| format |
Artigo |
| topic |
Review Article |
| spellingShingle |
Review Article Minnerup, Jens Schäbitz, Wolf-Rüdiger Multifunctional actions of approved and candidate stroke drugs |
| description |
Ischemic stroke causes brain damage by multiple pathways. Previous stroke trials have demonstrated that drugs targeting one or only a few of these pathways fail to improve clinical outcome after stroke. Drugs with multimodal actions have been suggested to overcome this challenge. In this review, we describe the mechanisms of action of agents approved for secondary prevention of ischemic stroke, such as antiplatelet, antihypertensive, and lipid-lowering drugs. These drugs exhibit considerable properties beyond their classical mechanisms, including neuroprotective and neuroregenerative properties. In addition, candidate stroke drugs currently studied in clinical phase III trials are described. Among these, albumin, hematopoietic growth factors, and citicoline have been identified as promising agents with multiple mechanisms. These drugs offer hope that additional treatment options for the acute phase after a stroke will become available in the near future. |
| author |
Minnerup, Jens Schäbitz, Wolf-Rüdiger |
| author_facet |
Minnerup, Jens Schäbitz, Wolf-Rüdiger |
| author_sort |
Minnerup, Jens |
| title |
Multifunctional actions of approved and candidate stroke drugs |
| title_short |
Multifunctional actions of approved and candidate stroke drugs |
| title_full |
Multifunctional actions of approved and candidate stroke drugs |
| title_fullStr |
Multifunctional actions of approved and candidate stroke drugs |
| title_full_unstemmed |
Multifunctional actions of approved and candidate stroke drugs |
| title_sort |
multifunctional actions of approved and candidate stroke drugs |
| publisher |
Springer-Verlag |
| container_title |
Neurotherapeutics |
| publishDate |
2009 |
| url |
https://ncbi.nlm.nih.gov/pmc/articles/PMC5084255/ https://ncbi.nlm.nih.gov/pubmed/19110198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nurt.2008.10.032 |
| _version_ |
1817934213561712640 |